Lin BioScience, Inc. (TPEX:6696)

Lin BioScience Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	9,632	11,908	1,488	3,261	1,645	806.85
Short-Term Investments	6,965	4,384	3,571	-	-	-
Trading Asset Securities	-	-	149.14	-	-	-
Cash & Short-Term Investments	16,597	16,293	5,208	3,261	1,645	806.85
Cash Growth	218.02%	212.82%	59.71%	98.21%	103.91%	-26.13%
Other Receivables	22.58	23.33	19.37	25.47	0.11	1.49
Receivables	22.58	23.33	19.37	25.47	0.11	1.49
Prepaid Expenses	236.23	139.93	123.27	137.69	-	-
Other Current Assets	1.2	0.16	0.35	0	27.01	11.21
Total Current Assets	16,857	16,456	5,351	3,424	1,672	819.54
Property, Plant & Equipment	111.14	37.98	50.66	58.91	65.86	5.4
Long-Term Investments	8,964	8,806	-	-	-	-
Other Intangible Assets	114.17	113.23	118.4	108.91	108.92	97.12
Other Long-Term Assets	21.92	12.96	6.68	4.69	4.94	1.17
Total Assets	26,069	25,426	5,527	3,597	1,852	923.23

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accrued Expenses	-	225.15	120.82	111.47	59.16	44.94
Current Portion of Leases	28.06	14.42	16.1	13.85	10.32	2.24
Other Current Liabilities	414.17	43.28	18.4	13.38	10.39	423.07
Total Current Liabilities	442.73	282.85	155.33	138.7	79.88	470.25
Long-Term Leases	64.66	8.4	17.89	29.03	36.18	-
Total Liabilities	507.39	291.24	173.22	167.73	116.06	470.25

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	829.2	828.27	786.3	785.16	723.19	689.9
Additional Paid-In Capital	10,423	14,101	4,827	3,477	1,935	1,029
Retained Earnings	-872.63	-4,269	-2,907	-2,162	-1,475	-1,162
Comprehensive Income & Other	213.24	73.26	148.35	37.34	51.55	-15.93
Total Common Equity	10,593	10,733	2,855	2,137	1,234	541.57
Minority Interest	14,968	14,402	2,499	1,292	501.86	-88.59
Shareholders' Equity	25,561	25,134	5,354	3,429	1,736	452.98
Total Liabilities & Equity	26,069	25,426	5,527	3,597	1,852	923.23

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	92.72	22.81	33.99	42.87	46.5	2.24
Net Cash (Debt)	16,505	16,270	5,174	3,218	1,599	804.61
Net Cash Growth	217.75%	214.43%	60.78%	101.30%	98.70%	-25.99%
Net Cash Per Share	199.28	198.15	65.83	43.50	22.29	11.70
Filing Date Shares Outstanding	82.87	82.83	78.63	78.52	72.32	68.99
Total Common Shares Outstanding	82.87	82.83	78.63	78.52	72.32	68.99
Working Capital	16,415	16,173	5,196	3,286	1,592	349.29
Book Value Per Share	127.83	129.58	36.31	27.22	17.07	7.85
Tangible Book Value	10,479	10,619	2,737	2,028	1,125	444.45
Tangible Book Value Per Share	126.45	128.21	34.80	25.84	15.56	6.44
Machinery	-	24.29	21.65	16.64	16.44	6.04
Leasehold Improvements	-	12.58	11.05	10.67	10.67	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 26, 2026

Data Sources Report a data error